Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Current Assets: 2015-2025

Historic Current Assets for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $219.6 million.

  • Voyager Therapeutics' Current Assets fell 41.20% to $219.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.6 million, marking a year-over-year decrease of 41.20%. This contributed to the annual value of $276.8 million for FY2024, which is 13.41% down from last year.
  • As of Q3 2025, Voyager Therapeutics' Current Assets stood at $219.6 million, which was down 3.64% from $227.9 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Current Assets registered a high of $409.1 million during Q1 2024, and its lowest value of $124.5 million during Q4 2022.
  • Over the past 3 years, Voyager Therapeutics' median Current Assets value was $282.2 million (recorded in 2023), while the average stood at $300.0 million.
  • In the last 5 years, Voyager Therapeutics' Current Assets tumbled by 41.66% in 2021 and then spiked by 156.78% in 2023.
  • Over the past 5 years, Voyager Therapeutics' Current Assets (Quarterly) stood at $136.7 million in 2021, then dropped by 8.92% to $124.5 million in 2022, then soared by 156.78% to $319.7 million in 2023, then decreased by 13.41% to $276.8 million in 2024, then plummeted by 41.20% to $219.6 million in 2025.
  • Its Current Assets stands at $219.6 million for Q3 2025, versus $227.9 million for Q2 2025 and $245.2 million for Q1 2025.